Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials

BACKGROUND: Specific ceramides have been identified as risk markers for cardiovascular disease (CVD) years before onset of disease. Treatment with the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide has been shown to induce beneficial changes in the lipid profile and reduce the risk o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wretlind, Asger, Curovic, Viktor Rotbain, de Zawadzki, Andressa, Suvitaival, Tommi, Xu, Jin, Zobel, Emilie Hein, von Scholten, Bernt Johan, Ripa, Rasmus Sejersten, Kjaer, Andreas, Hansen, Tine Willum, Vilsbøll, Tina, Vestergaard, Henrik, Rossing, Peter, Legido-Quigley, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521385/
https://www.ncbi.nlm.nih.gov/pubmed/37752566
http://dx.doi.org/10.1186/s12944-023-01922-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10521385/
https://www.ncbi.nlm.nih.gov/pubmed/37752566
http://dx.doi.org/10.1186/s12944-023-01922-z

Ejemplares similares